CAR-T Meeting 2024 | The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares some insights into the evolving role of autologous stem cell transplantation (autoSCT) in multiple myeloma with the emergence of novel immunotherapies, namely CAR-T cells. While several ongoing trials are evaluating CAR-T cells in this patient population, there is uncertainty around whether these agents will replace autoSCT, and more data are needed. Prof. Mohty also highlights the importance of improving accessibility and affordability of CAR-T cells, which remains a challenge in the field. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Gilead: Honoraria; GSK: Honoraria; Pfizer; Honoraria; Adaptive Biotechnologies: Honoraria; Oncopeptides: Honoraria; Astellas: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Amgen: Honoraria; Jazz Pharmaceuticals: Honoraria, Research Funding; Celgene: Honoraria; Bristol Myers Squibb: Honoraria; Sanofi: Honoraria, Research Funding; Janssen: Honoraria, Research Funding.
